Cor van den Bos
Overview
Explore the profile of Cor van den Bos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hochheuser C, Rozeman M, Kunze N, Gelineau N, Kuijk C, Jaspers-Bakker A, et al.
Stem Cells Dev
. 2025 Jan;
34(3-4):61-72.
PMID: 39817857
Autologous hematopoietic stem cell transplantation is used to restore bone marrow function after high-dose chemotherapy. For apheresis, granulocyte colony-stimulating factor (G-CSF) is standard of care, but obtaining sufficient stem cells...
2.
Kemps P, Woei-A-Jin F, Quint K, van den Bos C, Naeije L, van Laar J, et al.
Blood Adv
. 2024 Oct;
9(3):439-444.
PMID: 39361730
No abstract available.
3.
Kemps P, Baelde H, Vorderman R, Stelloo E, Swennenhuis J, Szuhai K, et al.
Blood
. 2024 Sep;
144(23):2439-2455.
PMID: 39316650
Juvenile xanthogranuloma (JXG) is a histiocytic neoplasm that usually presents in the skin. Rarely, extracutaneous localizations occur; the genetic drivers of this clinical variant of JXG remain incompletely characterized. We...
4.
Thus K, de Groot-Kruseman H, Winkler-Seinstra P, Fiocco M, Segers H, van den Bos C, et al.
Haematologica
. 2024 Aug;
110(1):47-54.
PMID: 39113674
Infections lead to substantial morbidity during the treatment of acute lymphoblastic leukemia (ALL) in which the adaptive immune system is severely affected, leading to declining serum immunoglobulin levels. We performed...
5.
van der Sluis I, Brigitha L, Fiocco M, de Groot-Kruseman H, Bierings M, van den Bos C, et al.
J Clin Oncol
. 2024 Feb;
42(14):1676-1686.
PMID: 38306592
Purpose: The primary objective of this randomized study was to determine whether a continuous dosing schedule (without the asparaginase-free interval) would result in less hypersensitivity reactions to PEGasparaginase (PEGasp) compared...
6.
Kemps P, Kester L, Scheijde-Vermeulen M, van Noesel C, Verdijk R, Diepstra A, et al.
Histopathology
. 2024 Jan;
84(5):837-846.
PMID: 38213281
Aims: The discovery of somatic genetic alterations established many histiocytic disorders as haematologic neoplasms. We aimed to investigate the demographic characteristics and additional haematologic cancers of patients diagnosed with histiocytic...
7.
Papadakis V, Astigarraga I, van den Bos C, Donadieu J, Henter J, Jacobs S, et al.
Pediatr Blood Cancer
. 2024 Jan;
71(3):e30850.
PMID: 38185727
No abstract available.
8.
Schwartz E, Rensen N, Steur L, Gemke R, van Eijkelenburg N, van der Sluis I, et al.
BMJ Open
. 2023 Oct;
13(10):e070804.
PMID: 37899146
Objectives: Health-related quality of life (HRQoL) is impaired in paediatric patients with acute lymphoblastic leukaemia (ALL). Over the past decades, ALL treatment has successfully been adjusted to the risk of...
9.
Uittenboogaard A, van den Berg M, Abbink F, Twisk J, van der Sluis I, van den Bos C, et al.
Cancer Med
. 2023 Sep;
12(19):19480-19490.
PMID: 37732486
Introduction: Vincristine is an integral component of treatment for children with cancer. Its main dose-limiting side effect is vincristine-induced peripheral neuropathy (VIPN). The VINCA trial was a randomized controlled trial...
10.
Acosta-Medina A, Kemps P, Zondag T, Abeykoon J, Forma-Borst J, Steenwijk E, et al.
Blood
. 2023 Aug;
142(18):1570-1575.
PMID: 37595284
In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence...